Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matilda Bingham

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Progress in Medicinal Chemistry|November 19, 2023
PrefaceJonathan Bentley, Matilda Bingham
Progress in Medicinal Chemistry|November 19, 2023
Biophysical screening and characterisation in medicinal chemistryMatilda Bingham, Thomas Pesnot, Andrew D Scott
Angewandte Chemie (International Ed. in English)|March 21, 2006
Ring-closing metathesis as a basis for the construction of aromatic compoundsTimothy J Donohoe, Allan J Orr, Matilda Bingham
Bioorganic & Medicinal Chemistry Letters|August 18, 2020
Novel C-7 carbon substituted fourth generation fluoroquinolones targeting N. Gonorrhoeae infectionsRalph Kirk, Mark Betson, Matilda Bingham, et al.
Cancer Research Communications|March 16, 2023
The Wnt Pathway Inhibitor RXC004 Blocks Tumor Growth and Reverses Immune Evasion in Wnt Ligand-dependent Cancer ModelsCaroline Phillips, Inder Bhamra, Catherine Eagle, et al.
Bioorganic & Medicinal Chemistry Letters|November 30, 2010
The identification, and optimisation of hERG selectivity, of a mixed NET/SERT re-uptake inhibitor for the treatment of painDerek Angus, Matilda Bingham, Dawn Buchanan, et al.
Bioorganic & Medicinal Chemistry Letters|May 24, 2011
Identification and optimisation of novel sulfonamide, selective vasopressin V1B receptor antagonistsJames Baker, Matilda Bingham, Ruth Blackburn-Munro, et al.
Bioorganic & Medicinal Chemistry Letters|June 25, 2011
Optimisation of pharmacokinetic properties to afford an orally bioavailable and selective V1A receptor antagonistWilliam Arbuckle, James Baker, David Barn, et al.
Bioorganic & Medicinal Chemistry Letters|April 5, 2011
The discovery of novel 8-azabicyclo[3.2.1]octan-3-yl)-3-(4-chlorophenyl) propanamides as vasopressin V1A receptor antagonistsSusan Napier, Grant Wishart, William Arbuckle, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Progress in Medicinal Chemistry|November 19, 2023
PrefaceJonathan Bentley, Matilda Bingham
Progress in Medicinal Chemistry|November 19, 2023
Biophysical screening and characterisation in medicinal chemistryMatilda Bingham, Thomas Pesnot, Andrew D Scott
Angewandte Chemie (International Ed. in English)|March 21, 2006
Ring-closing metathesis as a basis for the construction of aromatic compoundsTimothy J Donohoe, Allan J Orr, Matilda Bingham
Bioorganic & Medicinal Chemistry Letters|August 18, 2020
Novel C-7 carbon substituted fourth generation fluoroquinolones targeting N. Gonorrhoeae infectionsRalph Kirk, Mark Betson, Matilda Bingham, et al.
Cancer Research Communications|March 16, 2023
The Wnt Pathway Inhibitor RXC004 Blocks Tumor Growth and Reverses Immune Evasion in Wnt Ligand-dependent Cancer ModelsCaroline Phillips, Inder Bhamra, Catherine Eagle, et al.
Bioorganic & Medicinal Chemistry Letters|November 30, 2010
The identification, and optimisation of hERG selectivity, of a mixed NET/SERT re-uptake inhibitor for the treatment of painDerek Angus, Matilda Bingham, Dawn Buchanan, et al.
Bioorganic & Medicinal Chemistry Letters|May 24, 2011
Identification and optimisation of novel sulfonamide, selective vasopressin V1B receptor antagonistsJames Baker, Matilda Bingham, Ruth Blackburn-Munro, et al.
Bioorganic & Medicinal Chemistry Letters|June 25, 2011
Optimisation of pharmacokinetic properties to afford an orally bioavailable and selective V1A receptor antagonistWilliam Arbuckle, James Baker, David Barn, et al.
Bioorganic & Medicinal Chemistry Letters|April 5, 2011
The discovery of novel 8-azabicyclo[3.2.1]octan-3-yl)-3-(4-chlorophenyl) propanamides as vasopressin V1A receptor antagonistsSusan Napier, Grant Wishart, William Arbuckle, et al.
Pageof 1